HYNRCS-Allo - Corestem

Drug Profile

HYNRCS-Allo - Corestem

Alternative Names: Allogeneic bone marrow-derived mesenchymal stem cells (ALS) - Corestem; HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell

Latest Information Update: 07 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CORESTEM
  • Developer CORESTEM; Hanyang University
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Amyotrophic lateral sclerosis

Most Recent Events

  • 01 Feb 2017 Hanyang University and Corestem initiate a phase I trial for Amyotrophic lateral sclerosis in South Korea (Intrathecal) (NCT03214146)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top